Mine are here:
Address the complete problems in stroke.
And here:
These 177 hyperacute therapies that need more research.
And here:
My 31 ideas on hyperacute therapy I'm going to insist my doctor give me during the first week.
And here:
To test out these 17 diagnosis possibilities to find out which one is the best? Or maybe the Qualcomm Xprize for the tricorder?
And here:
Solve the neuronal cascade of death by these 5 causes in the first week.
https://www.statnews.com/2016/09/07/cancer-research-moonshot-panel-report/
A panel of top scientists is urging the Obama administration to bet big on tumor profiling and immunotherapy treatments in its cancer moonshot — two areas that are viewed with great promise, but still face unanswered questions about their ultimate effectiveness.
The experts are recommending the creation of a
new national network that would allow cancer patients across the country
to have their tumors genetically profiled
and included in a new national database — one of several recommended
steps that they say would significantly speed the progress of cancer
research in the United States.
The panel is also urging the creation of a network to coordinate clinical trials using immunotherapy, the promising new treatment that turns the body’s immune system against the disease.
article continues after advertisement
The recommendations are part of a report issued Wednesday by an expert panel advising the White House in its cancer moonshot initiative. It was formally accepted by the National Cancer Advisory Board Wednesday morning.
The tumor network would help scientists better
identify which treatments work for which cancers in which patients, the
panel said. As scientists become more aware of the many different kinds
of cancer, and turn increasingly to more personalized treatments, they see the profiling the genetics of individual tumors as crucial.
Patients would be connected with the hospitals and
cohorts across the country that profile tumors and those institutions
would share the collected data. The network would both aid in enrolling
specific patients in clinical trials that show promise for their cancer
by letting them “pre-register” for trials, the panel said, and allow
researchers to make broader observations about the genetic makeup of
different cancers and about which treatments are successful in fighting
them.
No comments:
Post a Comment